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The dramatic improvements which have occurred over the
past 20 years in the management of children and young
people with cancer, along with the recognition of significant
late effects of treatment, has led to a reappraisal of the
overall philosophy of management. At a time when most
children died of their disease a policy of cure 'at any cost'
was justified. Now we have moved into an era of cure 'at
least cost' (Morris Jones & Craft, 1990) and this is well
exemplified by the management of bone tumours in young
people. Indeed the 'Cade' approach to the management of
osteosarcoma, namely radiotherapy to the primary tumour
followed by delayed amputation if the patient had not
developed metastases, could be said to be a forerunner of this
philosophy in that its intention was to 'manage' at least cost.
Osteosarcoma and Ewing's tumour are the two common
malignant primary bone tumours which occur in children
and young adults with a peak incidence for both in the
teenage years. It is at this time of life that amputation can be
so devastating to a growing child with an everburgeoning
perception of their own body image. Amputation in this age
group is perhaps one of the most distressing forms of treat-
ment which doctors and nurses have to inflict on patients and
it is not surprising that alternative methods of therapy have
been sought. Limb salvage surgery therefore has developed
over the last 40 years in an attempt to mitigate the effects of
this mutilating surgery. In addition to en bloc resection and
replacement with a metal prosthesis other limb salvage
methods have also been developed. Amongst these is rotation
plasty (Kotz & Salzer, 1982), widely used for lower femoral
osteosarcoma in the remainder of Europe, but less so in the
UK, which consists of resection of the tumour bone and its
surrounding structure followed by rotation of the tibia
through 180' and its reimplantation on the remains of the
femur. The ankle then becomes the knee and the artificial
limb is attached to the foot. Critics of this form of surgery
suggest severe psychological distrubance may ensue but this
does not seem to be the case. Many consider it a modified
amputation.
The primary aim of treatment for any cancer must be to
cure the patient if at all possible. In the pre-chemotherapy
era, only 20% of patients with osteosarcoma were cured by
surgery alone and without chemotherapy or radiotherapy
virtually all patients with Ewing's sarcoma died. Death was
usually due to the development of distant metastases. The
advent of chemotherapy has resulted in a dramatic improve-
ment in survival for osteosarcoma patients to between 50 and
60% in most multi-institutional studies (Bramwell, 1987).
Chemotherapy and radiotherapy have led to a reported 50%
survival rate for Ewing's sarcoma (Craft, 1987). The treat-
ment for both tumour types is in two phases, one being the
definitive treatment of the primary tumour by surgery, radio-
therapy or both and the other is the treatment of covert
micrometastatic disease by chemotherapy. The latter usually
also has some effect on the primary tumour. The definitive
treatment of the primary tumour in osteogenic sarcoma must
be surgery if complete ablation is to succeed, whereas this is
often possible with a combination of chemotherapy and
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radiotherapy in Ewing's tumour. It is unlikely that, with the
present chemotherapeutic agents, osteosarcoma will ever be
cured without surgery. A recent report of 'flat bone' primary
osteosarcoma showed that only where complete surgical
excision was possible could cure be obtained (Kellie et al.,
1990). Although Ewing's tumour can be locally controlled by
radiotherapy this modality does have significant late effects
including radiation necrosis of bone with the risk of fracture,
contraction of soft tissue with tendon shortening and the
possibility of second malignancy (Tucker et al., 1977).
Because of these factors surgery has been employed more
often and recently been shown to be a safe, and perhaps even
a prognosticially beneficial option in the management of
Ewing's tumour (Gobel et al., 1987). Surgery should be
considered mandatory in treating osteosarcoma and, al-
though optional, may have some significant benefits in
managing Ewing's tumour.
If surgery is contemplated is limb salvage with prosthetic
replacement the preferred option? It is now more than 40
years since the first prosthetic replacement for a bone tumour
was carried out in the UK (Seddon & Scales, 1949) using a
hand carved 'polythene' prosthesis. Since then prostheses
production and their surgical implantation has grown
rapidly. Much of the knowledge of the prosthetic devices has
been a consequence of the experience in arthroplasty per-
formed for arthritic joints but the surgery itself has had to be
developed specifically with cancer in mind. That the surgery
can be successful is without doubt. Between 1949 and 1986
680 custom made prostheses were manufactured and inserted
at the two major national bone tumour centres in the UK in
London and Birmingham. Most of these were for cancer and
many patients have been long term survivors with a function-
ing prosthesis (Kemp, 1987).
In Europe the major group carrying out co-operative
studies in Ewing's tumour is the German CESS (Cooperative
Ewing's Sarcoma Study) group. In CESS 81 surgery for local
control was carried out in 60 (65%) of 93 patients, 14 (15%)
of these being extracompartmental resections rather than
amputation (Jurgens et al., 1988). In CESS 86 74% of
patients had primary surgery, 67% of these having resection
rather than amputation (H. Jurgens, personal communica-
tion). In the UK the MRC/UKCCSG have been involved in
the European Osteosarcoma Intergroup (EOI) studies for
osteosarcoma where there has again been an increasing use
of conservative surgery from 62% in the 80831 study to 70%
in 80861 (MRC unpublished data). Endoprosthetic replace-
ment surgery therefore has gained an increasing place in the
management of bone tumours in young people.
Clinicians working in this field can confidently expect some
patients to walk into the room following a prosthetic replace-
ment without any significant disability and to be leading a
virtually normal life. However they also see some patients in
whom there have been significant complications which may
even result in eventual amputation. The media are also con-
stantly showing us the incredible achievements of some of
those who have had an amputation, because often these
patients achieve more on one leg than most people achieve
with two legs. Has prosthetic implant therefore been worth-
while and is it better than the alternative of amputation or
for, Ewing's tumour, irradiation? It is worth assessing the
Br. J. Cancer (1991), 63, 173-175 (D Macmillan Press Ltd., 1991174 A.W. CRAFT
major criteria on which we can judge the usefulness of this
approach bearing in mind that it has been pioneered by a
small group of enthusiastic surgeons.
(a) Does endoprosthetic surgery affect survival?
The only way to be sure about this would be to conduct a
randomised study of amputation versus prosthetic replace-
ment between patients matched for age, sex, site and size of
tumour. It is unlikely that such a surgical trial would show
an improved overall survival for prosthetic replacement but it
is possible that there could be differences between the groups.
Local recurrence is theoretically more likely after local resec-
tion than it is following amputation. If this were so it would
lead to a decrease in disease free survival of the patients
receiving prosthetic implants and this could translate into
lower overall survival.
Chemotherapy is undoubtedly important in the manage-
ment of these high grade bone tumours. It is possible that by
inserting a massive surgical procedure into the middle of a
course of chemotherapy the drugs could be delayed or that
other complications such as major infection, could ensue,
which could compromise overall outcome. Once again this is
a difficult question to answer without a randomised study.
However, the influence of chemotherapy on perioperative
complications in limb salvage surgery has been investigated
at the Institute Rizzoli in Bologna (McDonald & Capanna,
1990). They compared the complications in three groups of
patients who had either adjuvant, neoadjuvant or no chemo-
therapy. Overall, infection was the most common complica-
tion occurring in 11.8% of the total of the three groups (304
patients). Taking all complications there was an incidence of
25.2% in the no chemotherapy group, 32.8% in the adjuvant
and 55.4% in the neoadjuvant group. Infection led to
amputation in eight of the most severely affected of the 36
patients who had this complication. This study seems to
suggest that chemotherapy does increase the incidence of
complications in limb salvage surgery, but we do not know if
this resulted in a significant change to the chemotherapy
regimen or to the ultimate survival of the patients.
It is much more difficult to comply with the requirements of
good cancer surgery with en bloc resection than it is with an
amputation. Inadvertent tumourcontamination ofthe wound is
a greater possibility in en bloc resection. The significance ofthis
was studied by Enneking (Enneking & Maale, 1988). They
found the incidence of local recurrence in known wound
contamination was substantial and that this could be best
influenced by immediate re-excision. Adjuvant chemotherapy
was of less benefit in preventing local recurrence.
Attempts have been made to compare survival in apparently
similar patients treated by either amputation or limb salvage
surgery. Simon and colleagues collected data from a number of
institutions in the United States andcould detect no difference in
survival according to type ofsurgery (Simon et al., 1986). Even
in patients treated on a common protocol in the US CCSG
studies, nodifferencein survival was seen with thedifferent types
of surgery (Makley & Krailo, 1988). However the results of a
multi-institutional study in Japan (Tomita & Tsuchiya, 1989)
and in Europe (Jurgens et al., 1988) contradict this showing
better survival for those who had limb salvage surgery but, as
both papers are careful to point out, this does not mean that
endoprostheses are beneficial for all patients. It may merely
reflect patient selection. Patients with smallertumours and those
who show a good response to pre-operative chemotherapy, two
well recognised good prognostic factors, are more likely to be
amenable to conservative procedures. The incidence of local
recurrence may be slightly higherwith limbpreservation surgery
but again this is controversial. A 5% local recurrence rate has
been reported in both types of surgery.
(b) Does endoprosthetic surgery improve the quality ofthe
patient's life?
There can be little doubt that cosmetically endoprosthetic
replacement is preferable to amputation. One or two longi-
tudinal scars with a diminished muscle bulk should be the
only residual outward signs following resection of a tumour
at the lower end of the femur. The functional outcome of
limb salvage surgery is much more difficult to assess. There is
often a misconception amongst patients that limb preserva-
tion surgery means conservation of a normal limb. This is
not so. Patients receiving an endoprosthesis may be able to
take part in limited sporting activity but there will always be
restrictions even on what the patient feels able to do. Con-
versely, following amputation, patients are allowed to do
whatever they feel able to do, the only risks being that they
may injure themselves if they fall or may break an artificial
limb which can be easily replaced, even if at a cost. Those
with endoprostheses must be careful not to stress their limb
unduly because of the risk of fracture or loosening of the
device with all of the attendant problems this will lead to.
There is no widely accepted method for evaluating out-
come of any musculoskeletal surgery. In the United States a
multi-million dollar grant has recently been awarded to study
this problem. The system devised by Enneking (1985) is
probably the best that is currently available, but because of
its complexities it has not been widely used. It concentrates
on seven primary factors i.e. motion, pain, stability, defor-
mity, strength, functional activity and emotional acceptance.
In terms of the patient's quality of life the latter two are the
most important although both depend on the other five
criteria. Clearly what a patient can or can't do is very
important. There has been little evaluation of this or any
other rating system in young people with bone cancer treated
by different surgical techniques. A Japanese multi-institu-
tional study did attempt to use the Enneking system in a
group ofpatients who had limb salvage surgery. In the first 2
years following surgery the number of patients rated 'excel-
lent' or 'good' was high but the number rated as 'fair' or
'poor' increased after a 4 year follow up mainly due to post
surgical complications (Tomita & Tsuchiya, 1989). Van der
Eyken (personal communication) carried out a study 'in the
field' of emotional adjustment and functional ability in a
group of 36 adolescents who had either endoprosthetic
replacement, amputation or rotationplasty and who were
taking part in a skiing holiday. There is no doubt that the
best adjusted and functionally most active were those who
had rotationplasty. However once again these patients were
selected for their particular surgical procedure and it may
well be that only the emotionally stable were offered rota-
tionplasty. Sugarbaker et al. (1982) studied the quality of life
in patients with soft tissue sarcomas treated by either
amputation or limb sparing surgery and was unable to show
any difference in the two gruops using well validated rating
scales. Indeed the only significant findings in the study were
that, when compared with limb salvage patients, amputees
were both better emotionally adjusted and had superior
'body care and movement' as well as having better scores for
'health care orientation' and 'sexular relationships'. A similar
result was also found by Weddington et al. (1985). An addi-
tional approach which can be studied when assessing func-
tional outcome is to measure the energy cost ofgait. Otis and
colleagues in New York (Otis et al., 1985) found that patients
who had endoprosthetic replacement had a significantly
lower energy cost during gait than those who had an ampu-
tation, but what this actually means for the patient is difficult
to assess.
(c) What are the relative rehabilitation times?
Amputation should lead to a short hospital stay and more
rapid rehabilitation. Early fitment of an external prosthesis,
where this is possible, and mobility education will lead to a
rapid return to at least limited mobility. Endoprosthetic
replacement on the other hand requires a much longer non
weight bearing period followed by graded activities to
achieve safe, maximum mobility. This may be interrupted by
infection and other complications in a significant number of
cases. In younger children who had a 'growing' prosthesis
inserted (Lewis, 1986) there is the additional problem ofPROSTHETIC REPLACEMENT SURGERY FOR BONE TUMOURS 175
repeated minor surgical procedures every 3 months in order
to lengthen the prosthesis. Most endoprostheses are put into
young active people who wish to lead a normal life and many
of these are likely to live a normal life span. The life span of
endoprosthetic devices is not known, but by extrapolation
from similar devices put into older, more sedentary people, it
is likely that many will require further revision surgery in 10
to 20 years.
(d) What are the relative costs?
Amputation only requires a few days in hospital and up to
2 h of theatre time. However there is the cost ofproviding an
external prosthetic device with replacement for the rest of a
patients life. Endoprosthetic replacement on the other hand
requires much longer in hospital, the cost of the device, up to
£1500, and there are several hours of theatre time. In addi-
tion the costs of hospitalisation for surgical complications
and revision surgery have to be taken into account. It is
likely therefore that endoprosthetic surgery will prove more
expensive over a lifetime.
(e) Otherfactors to be considered
At present custom made endoprosthetic surgery in the UK
has been developed at two major centres i.e. Birmingham and
London both of whom have recently received supraregional
funding for the service which they provide. Decentralisation
of this service has up until now been discouraged because of
the difficulties of providing custom made prostheses and the
need to concentrate and develop expertise. Because of the
considerable problems of travel and accomodation for
patients and their families from distant parts of the UK and
possible disruption of chemotherapy and continuing care,
other major regional centres have recently started to carry
out such procedures and are gaining the necessary expertise
to be able to provide an adequate service. However there are
as yet no recommendations as to the training required for
surgeons undertaking this type of procedure, to the facilities
and backup needed nor to the minimum number of patients
necessary to maintain expertise of all relevant disciplines
within a centre. Perhaps this is something which the British
Orthopaedic Association could address in association with
other disciplines. One of the major limiting factors in the
past has been the supply of custom made prostheses which,
in the UK have been manufactured at Stanmore and only
been made available to the two major centres. Many pros-
thetic devices are now commercially available and the
modular system designed by Kotz (Kotz & Engel, 1983) gives
the flexibility to 'design' the prosthesis at the time of surgery
in contrast to the complex preoperative assessment and delay
in manufacture of custom made devices.
Conspectus
Endoprosthetic surgery probably does not influence overall
survival. It is likely to be more expensive over a lifetime and
although it may produce better cosmetic results it may not
have any real functional advantage.
Endoprosthetic surgery for bone cancer is well established
and where available is likely to remain a favoured operation.
It is highly unlikely that agreement could ever be reached to
undertake a randomised study of endoprosthesis versus
amputation. Even if the doctors concerned could reach a
consensus it is likely that there would be very considerable
difficulties with patient randomisation. The best that can be
done is to prospectively collect and assess relevant surgical
and outcome data in the major therapeutic studies which are
now underway or are planned throughout the world. If a
simple, standardised form of functional assessment could be
devised and applied across studies then perhaps in the future
we would be able to discuss what really is best for this
important group of young active patients who now have a
good chance of being cured of their cancer. In the meantime,
we can offer endoprosthetic surgery where it is available, but
in the present state of knowledge there is nothing to suggest
that patients who have an amputation are receiving inferior
treatment.
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